搜索
Abcellera Biologics Inc
ABCL添加自选
7.600USD
-0.250-3.18%
收盘 07/01, 16:00（美东）报价延迟15分钟
2.31B总市值
亏损市盈率 TTM
关于 Abcellera Biologics Inc 公司
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc简介
公司代码ABCL
公司名称Abcellera Biologics Inc
上市日期Dec 11, 2020
CEOHansen (Carl L.G)
员工数量596
证券类型Ordinary Share
年结日Dec 11
公司地址150 W 4Th Avenue
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V5Y 1G6
电话16045599005
网址https://www.abcellera.com/
公司代码ABCL
上市日期Dec 11, 2020
CEOHansen (Carl L.G)
Abcellera Biologics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
常见问题
Abcellera Biologics Inc的前五大股东是谁？
Abcellera Biologics Inc 的前五大股东如下：Dr. Veronique Lecault, Ph.D.
有多少机构持有Abcellera Biologics Inc(ABCL)的股份？
截至2026Q1，共有323家机构持有Abcellera Biologics Inc的股份，合计持有的股份价值约为131.69M，占公司总股份的43.14%。与2025Q4相比，机构持股有所增加，增幅为-19217264.00。
哪个业务部门对Abcellera Biologics Inc的收入贡献最大？
在2026Q1，Licensing revenue业务部门对Abcellera Biologics Inc的收入贡献最大，创收46.92M，占总收入的62.45%。